drugset / Trial / NCT02538185
Intradermal Rabies Immunization Using NanoJect: A Comparative Study
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study is planned as a single-center, randomized, double-blind placebo-controlled, comparative Phase I, first-in-man study to assess the safety and tolerability of the NanoJect™ device, and the immunogenicity of the rabies vaccine "Vaccin rabique Pasteur®" delivered with the NanoJect™ device by ID route.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Vaccin rabique Pasteur® | Vaccine | 0.1 ml | Other |
| Comparator | Vaccin rabique Pasteur® | Vaccine | 0.5 ml | Other |
Indications
No indication recorded.